LJPC 401

Drug Profile

LJPC 401

Alternative Names: LJPC-401

Latest Information Update: 17 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator INSERM
  • Developer INSERM; La Jolla Pharmaceutical Company
  • Class Anti-infectives; Antimicrobial cationic peptides; Peptide hormones; Peptides; Proteins
  • Mechanism of Action Hepcidin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Beta-thalassaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Iron overload

Most Recent Events

  • 17 May 2017 La Jolla Pharmaceutical plans a phase I trial in Healthy volunteers in Australia (ACTRN12617000689370)
  • 01 Dec 2016 LJPC 401 receives Orphan Drug status for Sickle cell anaemia in European Union (La Jolla Pharma Annual report 2016)
  • 07 Sep 2016 Adverse events and efficacy data from a phase I trial in Iron overload released by La Jolla
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top